Open-label Study of TH-302 as Monotherapy and in Combination With Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Sponsors and Collaborators
Threshold Pharmaceuticals
Contact
Clarence Eng, MPH
650-474-8222
Investigator
Irene Ghobrial, MD
Massachusetts General Hospital
ClinicalTrials.gov Identifier
NCT01522872
Continue Reading
